Axa S.A. Esperion Therapeutics, Inc. Transaction History

Axa S.A.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.46 - $7.3 $9,170 - $45,851	-6,281 Reduced 0.8%	782,085 $1.24 Million
Q4 2022 Feb 14, 2023	BUY	$5.09 - $8.5 $4.01 Million - $6.7 Million	788,366 New	788,366 $4.91 Million
Q1 2021 May 14, 2021	BUY	$25.12 - $36.89 $926,274 - $1.36 Million	36,874 Added 40.85%	127,146 $3.57 Million
Q4 2020 Feb 12, 2021	BUY	$24.2 - $35.76 $1.74 Million - $2.57 Million	71,877 Added 390.74%	90,272 $2.35 Million
Q3 2020 Nov 13, 2020	SELL	$31.18 - $52.71 $5,799 - $9,804	-186 Reduced 1.0%	18,395 $684,000
Q2 2020 Aug 14, 2020	BUY	$30.04 - $51.31 $28,628 - $48,898	953 Added 5.41%	18,581 $953,000
Q1 2020 May 15, 2020	SELL	$27.44 - $73.84 $1.77 Million - $4.77 Million	-64,632 Reduced 78.57%	17,628 $556,000
Q4 2019 Feb 18, 2020	BUY	$35.4 - $59.82 $2.91 Million - $4.92 Million	82,260 New	82,260 $4.91 Million
Q2 2018 Aug 13, 2018	SELL	$36.2 - $76.4 $170,140 - $359,080	-4,700 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$65.94 - $80.76 $309,918 - $379,572	4,700 New	4,700 $340,000

206

128M

1.67M

930K

Ticker ESPR
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,551,600
Market Cap $153M
Description
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

Stay updated on Axa S.A. with notifications on news.